United States: EMQN CIC Oncopanel EQA Program

United States
Collaboration

General details

Recent therapeutic developments in NGS are revolutionizing biomarker detection in oncology however, only a slow transition towards the use of comprehensive genomic assessment has been observed irrespective, of the fact that many labs are equipped with these NGS platforms.

As part of this collaboration, you will:

• Receive Diaceutics sponsored enrollment onto the Oncopanel 20 EQA module. This program is being offered for labs using high through put technologies (e.g., NGS, MassArray etc) to help accurately validate assay sensitivity and specificity. Please visit the EMQN website for further details
• Contribute insight to support publication of a white paper article that focuses on day to day considerations that influence NGS adoption for clinical testing purposes

Enrolment for the 2021 Oncopanel module is active from 21st September 2020 to 31st March 2021. Please note that this collaboration may close early if the maximum number of participants has been met before the 31st March 2021. Should you be interested in this collaboration, we recommend that the lab profile and assay information is completed as soon as possible, as per defined requirements, to ensure your participation in this module.

Requirements

To be eligible to participate in this collaboration please ensure that:
1. Lab profile information reflects:
a. Available in-house NGS/real-time PCR platform details
b. External Quality Assurance (EQA) schemes or proficiency testing (PT) programs that are being subscribed to for molecular NSCLC biomarkers

2. Lab assay details reflecting
a. At least 3 of the following molecular NSCLC biomarkers
• EGFR
• BRAF
• KRAS
• MET (including ex14 skipping)
• NTRK fusions
• RET fusions and mutations

Documentation

Booking policies

Cancellation policy: Flexible

> If the asker cancels more than 1 day(s) before the start of the booking, he is reimbursed 100 % of the amount paid
> If the asker cancels less than 1 day(s) before the start of the booking , he is reimbursed 50 % of the amount paid

Requirements

To be eligible to participate in this collaboration please ensure that:
1. Lab profile information reflects:
a. Available in-house NGS/real-time PCR platform details
b. External Quality Assurance (EQA) schemes or proficiency testing (PT) programs that are being subscribed to for molecular NSCLC biomarkers

2. Lab assay details reflecting
a. At least 3 of the following molecular NSCLC biomarkers
• EGFR
• BRAF
• KRAS
• MET (including ex14 skipping)
• NTRK fusions
• RET fusions and mutations

Location

Calendar

Diaceutics

United Kingdom

Member since 13 Aug, 2020
Ask a question or directly offer to participate in a collaboration.